SEC Form 4 · accession 0001209191-17-005970
PLUS THERAPEUTICS, INC. · CNSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ron Martell
Director
Period of report
Jan 26, 2017
Accepted (ET)
Jan 27, 2017 · 5:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001095981
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F2 | $1.56 | Jan 26, 2017 | A | 50,000 | A | — | Jan 26, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56.
- F2Fifty percent (50%) of the option shares shall vest on January 26, 2018 with the remaining fifty percent (50%) of the option shares vesting on January 26, 2019.